PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Nature Medicine

• Publication date

  2014-06-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/nm.3552PMID 24929950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.

  2013cited by this paper
• MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells

  2011cited by this paper
• The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation

  2011cited by this paper
• Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model.

  2011cited by this paper
• Targeting the tumour vasculature: insights from physiological angiogenesis

  2010cited by this paper
• Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis.

  2009cited by this paper
• A Meta-Analysis

  2009cited by this paper
• Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein.

  2009cited by this paper
• Thrombotic events in patients with cancer receiving antiangiogenesis agents.

  2009cited by this paper
• Investigation of prolactin-related vasoinhibin in sera from patients with diabetic retinopathy.

  2009cited by this paper
• Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth.

  2009cited by this paper
• Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis.

  2008cited by this paper
• The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk.

  2008cited by this paper
• Vasoinhibins prevent retinal vasopermeability associated with diabetic retinopathy in rats via protein phosphatase 2A-dependent eNOS inactivation.

  2008cited by this paper
• Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

  2008cited by this paper
• A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy.

  2007cited by this paper
• Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.

  2007cited by this paper
• Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia

  2007cited by this paper
• TAFIa, PAI‐1 and α2‐antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots

  2007cited by this paper
• uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view

  2007cited by this paper
• The angiostatic 16K human prolactin overcomes endothelial cell anergy and promotes leukocyte infiltration via nuclear factor-kappaB activation.

  2007cited by this paper
• 16-kDa prolactin inhibits endothelial cell migration by down-regulating the Ras-Tiam1-Rac1-Pak1 signaling pathway.

  2007cited by this paper
• Inhibition of tumor growth and metastasis establishment by adenovirus-mediated gene transfer delivery of the antiangiogenic factor 16K hPRL.

  2007cited by this paper
• Vasoinhibins: endogenous regulators of angiogenesis and vascular function.

  2006cited by this paper
• Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis.

  2006cited by this paper
• Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy

  2006cited by this paper
• The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases.

  2005cited by this paper
• Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth

  2004cited by this paper
• Plasminogen activator inhibitor-1.

  2004cited by this paper
• The antiangiogenic factor 16K human prolactin induces caspase-dependent apoptosis by a mechanism that requires activation of nuclear factor-kappaB.

  2003cited by this paper
• Lack of Plasminogen Activator Inhibitor-1 Enhances the Preventive Effect of DX-9065a, a Selective Factor Xa Inhibitor, on Venous Thrombus and Acute Pulmonary Embolism in Mice

  2003cited by this paper
• Antitumor activity of the 16-kDa prolactin fragment in prostate cancer.

  2003cited by this paper
• Plasminogen Activator Inhibitor-1 Regulates Tumor Growth and Angiogenesis*

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• The Plasminogen Activator Inhibitor PAI-1 Controls in Vivo Tumor Vascularization by Interaction with Proteases, Not Vitronectin

  2001cited by this paper
• Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice.

  2001cited by this paper
• JCB Article

  2001cited by this paper
• Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation.

  2000cited by this paper
• The antiangiogenic factor 16K PRL induces programmed cell death in endothelial cells by caspase activation.

  2000cited by this paper
• Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis.

  1999cited by this paper
• Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance.

  1999cited by this paper
• 16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells.

  1999cited by this paper
• Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization

  1998cited by this paper
• Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice.

  1997cited by this paper
• Identification of functional synergism between monoclonal antibodies. Application to the enhancement of plasminogen activator inhibitor‐1 neutralizing effects

  1997cited by this paper
• Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.

  1996cited by this paper
• Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin.

  1995cited by this paper
• alpha-2 Macroglobulin receptor/Ldl receptor-related protein(Lrp)- dependent internalization of the urokinase receptor

  1995cited by this paper
• Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop.

  1995cited by this paper
• Physiological consequences of loss of plasminogen activator gene function in mice

  1994cited by this paper
• Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness

  1993cited by this paper
• Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization.

  1993cited by this paper
• A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.

  1992cited by this paper
• A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells.

  1992cited by this paper
• Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin.

  1991cited by this paper
• Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin).

  1988cited by this paper
• Immunological characterization of plasminogen activator activities in human tissues and body fluids.

  1981cited by this paper
• Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo.

  1978cited by this paper
• Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria.

  1973cited by this paper
• Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2 2 DD C T Method

  year unknowncited by this paper

• Advances in biomarker discovery for peripartum cardiomyopathy: current status and future directions

  2025cites this paper
• Integrin α5β1 mediates the inhibitory effects of vasoinhibin on angiogenesis and vascular permeability

  2025cites this paper
• Topical ophthalmic administration of the antiangiogenic peptide VIAN-c4551 protects against experimental diabetic macular edema

  2025cites this paper
• The antiangiogenic peptide VIAN-c4551 inhibits lung melanoma metastasis in mice by reducing pulmonary vascular permeability

  2025cites this paper
• PAI-1-driven SFRP2high cancer-associated fibroblasts hijack the abscopal effect of radioimmunotherapy.

  2025cites this paper
• Peripartum cardiomyopathy in low- and middle-income countries.

  2024cites this paper
• Topical Ophthalmic Administration of VIAN-c4551 Antiangiogenic Peptide for Diabetic Macular Edema: Preclinical Efficacy and Ocular Pharmacokinetics

  2024cites this paper
• Peripartum cardiomyopathy vs Peripartum Cardiomyopathy with preeclampsia: from biomolecular approach to management

  2024cites this paper
• The need for Cre-loci controls in conditional mouse experiments: Mrp8-cre transgene predisposes mice to antibody-induced arthritis

  2024cites this paper
• The 14-Kilodalton Human Growth Hormone Fragment a Potent Inhibitor of Angiogenesis and Tumor Metastasis

  2023cites this paper
• Immunometric and functional measurement of endogenous vasoinhibin in human sera

  2023cites this paper
• Vasoinhibin’s Apoptotic, Inflammatory, and Fibrinolytic Actions Are in a Motif Different From Its Antiangiogenic HGR Motif

  2023influential citation
• The significance of prolactin in systemic connective tissue diseases

  2023cites this paper
• 14K prolactin derived 14‐mer antiangiogenic peptide targets bradykinin‐/nitric oxide‐cGMP‐dependent angiogenesis

  2023cites this paper
• The apoptotic, inflammatory, and fibrinolytic actions of vasoinhibin are in a motif different from its antiangiogenic HGR motif

  2023influential citation
• Immunomodulatory role of decidual prolactin on the human fetal membranes and placenta

  2023cites this paper
• Successful management of peripartum cardiomyopathy in a Kenyan setting: a case series

  2023cites this paper
• Resistance to antiangiogenic treatments: A review

  2022cites this paper
• Prolactin and vasoinhibin are endogenous players in diabetic retinopathy revisited

  2022cites this paper
• The role of prolactin/vasoinhibins in cardiovascular diseases

  2022cites this paper
• Endothelial Dysfunction in the Context of Blood–Brain Barrier Modeling

  2022cites this paper
• Animal Models of Cardiovascular Complications of Pregnancy

  2022cites this paper
• Dual Roles of Prolactin and Vasoinhibin in Inflammatory Arthritis

  2022cites this paper
• New horizons in specific hormone proteolysis.

  2022cites this paper
• Vasoinhibin is Generated and Promotes Inflammation in Mild Antigen-Induced Arthritis.

  2022cites this paper
• A Comparative Phylogenetic Analysis of Prolactin Cleavage Sites for the Generation of Vasoinhibin In Vertebrates.

  2022cites this paper
• Pathophysiology and risk factors of peripartum cardiomyopathy

  2022cites this paper
• Development of Vasoinhibin-Specific Monoclonal Antibodies

  2021cites this paper
• The Plasminogen–Activator Plasmin System in Physiological and Pathophysiological Angiogenesis

  2021cites this paper
• Therapeutic Potential

  2021cites this paper
• The Relevant Participation of Prolactin in the Genesis and Progression of Gynecological Cancers

  2021cites this paper
• Plasmin generates vasoinhibin-like peptides by cleaving prolactin and placental lactogen.

  2021cites this paper
• Inhibition of cardiac PERK signaling promotes peripartum cardiac dysfunction

  2021cites this paper
• Thrombin cleaves prolactin into a potent 5.6 kDa vasoinhibin: Implication for tissue repair.

  2021cites this paper
• Peripartum cardiomyopathy and pre‐eclampsia: two tips of the same iceberg

  2021cites this paper
• The molecular mechanism of LRP1 in physiological vascular homeostasis and signal transduction pathways.

  2021cites this paper
• COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects

  2021cites this paper
• Heat Shock Proteins: Potential Modulators and Candidate Biomarkers of Peripartum Cardiomyopathy

  2021cites this paper
• The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide

  2021cites this paper
• Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

  2021cites this paper
• Vasoinhibin generation and effect on neuronal apoptosis in the hippocampus of late mouse embryos.

  2020cites this paper
• Peripartum cardiomyopathy: basic mechanisms and hope for new therapies.

  2020cites this paper
• The Role of Multimodality Cardiovascular Imaging in Peripartum Cardiomyopathy

  2020cites this paper
• Pregnancy-associated cardiac dysfunction and the regulatory role of microRNAs

  2020cites this paper
• Vasoinhibin reduces joint inflammation, bone loss, and the angiogenesis and vasopermeability of the pannus in murine antigen-induced arthritis

  2020cites this paper
• Diverse homeostatic and immunomodulatory roles of immune cells in the developing mouse lung at single cell resolution

  2020cites this paper
• Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic Retinopathy

  2020cites this paper
• The role of the prolactin receptor pathway in the pathogenesis of glioblastoma: what do we know so far?

  2020cites this paper
• In peripartum cardiomyopathy Plasminogen Activator Inhibitor-1 is a potential new biomarker with controversial roles.

  2019cites this paper
• Endothelial miR-30c suppresses tumor growth via inhibition of TGF-&bgr;–induced Serpine1

  2019cites this paper
• The Role of Fibrinolytic Regulators in Vascular Dysfunction of Systemic Sclerosis

  2019cites this paper
• Impact of Diabetes Mellitus on Human Mesenchymal Stromal Cell Biology and Functionality: Implications for Autologous Transplantation

  2019cites this paper
• A Current Approach to Hyperprolactinemia

  2019cites this paper
• Synergy Between Low Dose Metronomic Chemotherapy and the pH-Centered Approach Against Cancer

  2019cites this paper
• cardiac diseases using human stem cell-derived cardiomyocytes

  2019cites this paper
• Heart Disease in Pregnancy

  2019cites this paper
• Peripartum Cardiomyopathy: a Review

  2019cites this paper
• Sequence optimization and glycosylation of vasoinhibin: Pitfalls of recombinant production.

  2019cites this paper
• Regulator of Angiogenesis and Vascular Function: A 2019 Update of the Vasoinhibin Nomenclature

  2019cites this paper
• Differential activity of 16K rat prolactin in different organic systems

  2019cites this paper
• Anticoagulant and Antithrombotic Properties in Vitro and in Vivo of a Novel Sulfated Polysaccharide from Marine Green Alga Monostroma nitidum

  2019cites this paper
• Peripartum cardiomyopathy-diagnosis, management, and long term implications.

  2019cites this paper
• THE INFLUENCE OF HYPERPROLACTINEMIA ON THE LEVEL OF ESTRADIOL AND PROGESTERONE IN WOMEN

  2019cites this paper
• Comorbidities and Co-Existing Conditions in Heart Failure Around Pregnancy

  2019cites this paper
• Vasoinhibin comprises a three-helix bundle and its antiangiogenic domain is located within the first 79 residues

  2018cites this paper
• 16 kDa vasoinhibin binds to integrin alpha5 beta1 on endothelial cells to induce apoptosis

  2018cites this paper
• Incidence, Risk Factors, and Clinical Characteristics of Peripartum Cardiomyopathy in South Korea

  2018cites this paper
• Regulation of Extra-Pituitary Prolactin in Monocytes and Macrophages

  2018cites this paper
• Peripartum cardiomyopathy: An epidemiologic study of early and late presentations.

  2018cites this paper
• Understanding Peripartum Cardiomyopathy.

  2018cites this paper
• Hemorrhagic disorders of fibrinolysis: a clinical review

  2018cites this paper
• Peptides as a strategy against biofilm‐forming microorganisms: Structure‐activity relationship perspectives

  2018cites this paper
• Remarks on the Prolactin Hypothesis of Peripartum Cardiomyopathy

  2017cites this paper
• Peripartum cardiomyopathy: diagnosis and management

  2017cites this paper
• Role of ZEB1 in Tumor Progression: Regulation of Cell Invasion and Senescence

  2017cites this paper
• From Bench to Bedside: Translating the Prolactin/Vasoinhibin Axis

  2017cites this paper
• Human Prolactin Point Mutations and Their Projected Effect on Vasoinhibin Generation and Vasoinhibin-Related Diseases

  2017cites this paper
• Dual contribution of TRPV4 antagonism in the regulatory effect of vasoinhibins on blood-retinal barrier permeability: diabetic milieu makes a difference

  2017cites this paper
• Vasoinhibin Suppresses the Neurotrophic Effects of VEGF and NGF in Newborn Rat Primary Sensory Neurons

  2017cites this paper
• A circadian prelude to regulation of angiogenesis and thrombosis by prolactin and plasminogen activator inhibitor-1

  2016cites this paper
• Explorin the role of FIS1 in mitochondrial (patho)physiology

  2016cites this paper
• The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies

  2016cites this paper
• Peripartum Cardiomyopathy.

  2016cites this paper
• The effects of pituitary and thyroid disorders on haemostasis: potential clinical implications

  2016cites this paper
• The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview

  2016cites this paper
• Adipose Tissue-Derived Plasminogen Activator Inhibitor-1 Function and Regulation.

  2016cites this paper
• Prolactin protects retinal pigment epithelium by inhibiting sirtuin 2-dependent cell death

  2016cites this paper
• Arany and Elkayam Peripartum Cardiomyopathy 1399

  2016cites this paper
• Prolactin alters blood pressure by modulating the activity of endothelial nitric oxide synthase

  2016cites this paper
• Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

  2015cites this paper
• Soluble factors regulated by epithelial–mesenchymal transition mediate tumour angiogenesis and myeloid cell recruitment

  2015cites this paper
• New insights in prolactin: pathological implications

  2015cites this paper
• Regulation of blood vessels by prolactin and vasoinhibins.

  2015cites this paper
• Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis.

  2015cites this paper
• Principles of the prolactin/vasoinhibin axis

  2015influential citation
• Involvement of miR-34c in high glucose-insulted mesenchymal stem cells leads to inefficient therapeutic effect on myocardial infarction.

  2015cites this paper
• The Great Escape; the Hallmarks of Resistance to Antiangiogenic Therapy

  2015cites this paper
• The impact of inflammation on pregnancy outcomes

  2015cites this paper
• Corrigendum: PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

  2014cites this paper
• Pathophysiology and risk factors of peripartum 1 cardiomyopathy 2

  year unknowncites this paper